Hydroxyapatite (HA) (HA)

Hydroxyapatite [Ca10(PO4)6(OH)2] is the primary inorganic constituent of the bone matrix, providing the essential structural integrity and mechanical strength required for the vertebrate skeleton (StatPearls: NBK513314). It exists as carbonated nanocrystals deposited within and between collagen fibrils, serving as a critical reservoir for systemic calcium and phosphate homeostasis (PubMed: 31505436). In pathological states such as osteoporosis, Paget's disease, and bone metastases, the mineral matrix undergoes excessive resorption or disorganized deposition, which severely compromises skeletal stability (NCBI: PMC6539248). Hydroxyapatite serves as a unique therapeutic target due to its high affinity for specific chemical moieties, most notably the P-C-P bond found in bisphosphonates, allowing these drugs to concentrate specifically at sites of active bone remodeling (PubChem: CID 14781). This targeting mechanism is also extensively exploited in nuclear medicine, where radiopharmaceuticals like Technetium-99m methylene diphosphonate (MDP) bind to the mineral surface for diagnostic skeletal imaging (PubMed: 28430491). Furthermore, alpha-emitting isotopes like Radium-223 mimic calcium to integrate into the hydroxyapatite matrix, providing targeted radiotherapy for bone metastases (NIH: Xofigo).

Other names

HydroxylapatiteCalcium apatiteBone mineralCrystalline bone mineralBone hydroxyapatite mineral matrixDurapatite

Drugs target this matrix through high-affinity chelation of calcium ions on the hydroxyapatite crystal surface, which facilitates bone-specific localization and the subsequent inhibition of osteoclast-mediated bone resorption (StatPearls: NBK470248).